Podcasts about randomised

SIBO & Parasite Antimicrobial Protocol: https://drruscio.com/biofilm-protocol/?nab=0&utm_source=youtube  Elemental Diet: https://store.drruscio.com/pages/elementalheal  Triple Therapy Probiotics: https://store.drruscio.com/products/triple-therapy-probiotic  Gut Rebuild Nutrients: https://store.drruscio.com/products/gut-rebuild-nutrients-powder-chocolate?srsltid=AfmBOopnMhnrTlDklAWPUIyuoOFwM3FwTahLXX4888KzfgBc-Ym9bUvt    Parasites are an often-overlooked factor in chronic gut symptoms, food intolerance, histamine-type reactions, fatigue, and cases where patients feel stuck despite addressing SIBO, Candida, or other common gut imbalances. In this episode, Dr. Ruscio, Dr. Jake Vonfeldt, and Dr. Scott Spiridigliozzi discuss common parasites like Giardia, Cryptosporidium, Blastocystis, pinworms, and helminths, why standard testing can miss them, and how clinical history can help determine when parasites deserve closer consideration. They also share both natural and pharmaceutical parasite protocols, along with practical guidance on when each approach may be appropriate.   ✅Start healing with us! Learn more about our virtual clinic:  https://drruscio.com/virtual-clinic/

Our editors – Marc Bonten, Erin McCreary, Anne-Grete Märtson, Angela Huttner, and Josh Davis – are back for part two of the ESCMID Global Late Breakers series, summarising five more late-breaking trials presented at ESCMID Global 2026. They discuss the trials' strengths and weaknesses, and whether their results should change practice. The five trials presented in this half of the series are listed below, and links to their respective sessions can be watched and rewatched on the ESCMID Global Virtual Platform. Links to corresponding abstracts and publications where available are provided as well.Conflict of interest/involvement in the trials:Marc Bonten was the chair of the E.mbrace trial's steering committeeJosh Davis is global co-lead of the SNAP trialJosh Davis was a site investigator on the E.mbrace trialAngela Huttner was an independent/unpaid member of the E.mbrace trial's steering committee and an investigator on the precursor phase 1 trial testing the E. coli vaccinePROCALBAN trial (Late-breaking clinical trials in sepsis management)Chowdhury F, et al. Use of Procalcitonin Point-Of-Care Testing to Guide De-Escalation of Antibiotic Therapy in Adult Sepsis Patients in a Tertiary Hospital in Bangladesh: A Randomised Controlled Open-Label Trial, Preprints with The Lancet, doi: 10.2139/ssrn.6541698BENEFICIAL trial (Late-breaking clinical trials in sepsis management) De Cock PA, et al. Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial. Lancet Child Adolesc Health, doi: 10.1016/S2352-4642(25)00385-2  SNAP trial (Late-breaking clinical trials in sepsis management) Bowen A. Adjunctive clindamycin for treatment of Staphylococcus aureus bacteraemia: a randomised controlled trial within the S. aureus Network Adaptive Platform (SNAP), abstractAdjunctive betamethasone treatment of hypoxemic adults hospitalised with Mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial (Late-breaking research from The Lancet)Hagman K, et al. Adjunctive betamethasone treatment of hypoxaemic adults hospitalised with Mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial. Lancet 2026, doi: 10.1016/j.lanepe.2026.101610E.mbrace trial (Vaccines: landmark trials and preventive immunisation)Cohen CA, et al. Randomised phase III trial of a 9-valent vaccine (ExPEC9V) for prevention of invasive Escherichia coli disease (IED) in older adults (E.mbrace), abstractThe Swiss multicentre phase 1, first-in-human trial testing the conjugate E. coli vaccine:Huttner A et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 2017: May;17(5):528-537

Dr. Isabella Mahe is the first author of the API-CAT trial and in this episode she reviews predictors associated with clinically relevant bleeding. Join us for for an in-depth discussion on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism: a post-hoc analysis of a randomised, non-inferiority trial (API-CAT).

Send us Fan MailO que você oferece nas primeiras semanas importa — e muitoQuatro estudos. Quatro perguntas que todo neonatologista e pediatra já enfrentou na prática. Voltamos a apresentar os artigos do livro 50 Estudos que Todo Neonatologista Deve Conhecer, dessa vez com os artigos que revolucionaram a nutrição neonatal.Qual fórmula dar a um prematuro quando o leite materno não está disponível? Promover o aleitamento de forma estruturada realmente muda desfechos clínicos? Leite doado é superior à fórmula para prematuros extremos? E como manejar a hipoglicemia neonatal sem separar mãe e bebê?Neste episódio da Incubadora, discutimos os ensaios de Lucas et al. no BMJ, o PROBIT no JAMA, o DoMINO no JAMA e o Sugar Babies no Lancet — estudos que, juntos, constroem um argumento difícil de ignorar: decisões tomadas nas primeiras horas e semanas de vida deixam marcas que aparecem no pulmão, no cérebro e no desenvolvimento anos mais tarde.1.     Randomised trial of early diet in preterm babies and later intelligence quotient  - https://pubmed.ncbi.nlm.nih.gov/9831573/2.     Promotion of Breastfeeding Intervention Trial (PROBIT) A Randomized Trial in the Republic of Belarus - https://pubmed.ncbi.nlm.nih.gov/11242425/3.     Effect of Supplemental Donor Human Milk Compared With Preterm Formula on Neurodevelopment of Very Low-Birth-Weight Infants at 18 Months A Randomized Clinical Trial - https://pubmed.ncbi.nlm.nih.gov/27825008/4.     Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial - https://pubmed.ncbi.nlm.nih.gov/24075361/Evidência, cuidado e contexto brasileiro — esse é o nosso roteiro. Não esqueça: você  pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação.Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.orgEvidência, cuidado e contexto brasileiro - esse é o nosso roteiro.

Welcome to today's Midlife Minute. Today, we're exploring bloating, constipation, and various other midlife gut woes.  Stay tuned as I clarify how midlife changes the gut narrative and review the evidence about how to get things moving again. IN THIS EPISODE, YOU WILL LEARN: Why your gut motility changes in midlife How menopause influences the gut-brain connection Why various types of constipation require different interventions How changes in your gut bacteria affect the way your gut functions in menopause How different types of fiber can either help or worsen constipation symptoms, depending on the type of constipation  The main types of constipation, and how they differ  How estrogen therapy may influence bowel regularity, and why the route of administration matters Lifestyle habits that can stimulate bowel movements Why bloating tends to occur in midlife Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Links: 1. Menopause Is Associated with an Altered Gut Microbiome and Estrobolome, with Implications for Adverse Cardiometabolic Risk in the Hispanic Community Health Study/Study of Latinos 2. The Intestinal Microbiome and Estrogen Receptor–Positive Female Breast Cancer  3. Estrogen–gut microbiome axis: Physiological and clinical implications 4. Menopausal shift on women's health and microbial niches 5. Gut microbiota has the potential to improve health of menopausal women by regulating estrogen 6. Gut-microbiota-targeted diets modulate human immune status 7. Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women 8. Constipation and diarrhea during the menopause transition and early postmenopause: observations from the Seattle Midlife Women's Health Study 9. Estrogen Rather Than Progesterone Cause Constipation in Both Female and Male Mice 10. Rome IV Criteria 11. Gut-Directed Hypnotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis  Gut-Directed Hypnotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis (PubMed) 12. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome 13. Gut-directed hypnosis and hypnotherapy for irritable bowel syndrome: a mini-review 14. Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Enoch Akowuah, an academic consultant cardiothoracic surgeon at Newcastle University and South Tees NHS Foundation Trust, UK, and Dr. Matthias Raschpichler, a cardiac surgeon at Leipzig Heart Center, Germany, about the REPEAT trial. Chapters 00:00 Intro 02:21 JANS 1, NOBLE Trial 07:14 JANS 2, Ischemic Mitral Regurg MVR 08:58 JANS 3, Pregnancy Outcomes AVR 11:19 JANS 4, MCS LVAD Candidates 13:06 Video 1, Thoracoplasty 14:58 Video 2, Nuss Procedure After Ravitch 16:42 Video 3, Traumatic Right Main Bronchus 19:04 REPEAT Trial, Bioprostheses 32:22 Upcoming Events 32:46 Closing They discussed the trial's objectives, including what it is, why it is needed, and its overall goals. The setup of the trial was also examined, covering aspects such as funding, composite outcome, and follow-up procedures. Additionally, they addressed the target number of patients required for recruitment and the efforts involved in recruiting patients and centers to participate in the trial. They emphasized the overall significance of the trial, outlining what is necessary for its success and highlighting the importance of collaboration among heart teams. Joel also highlights recent JANS articles on percutaneous coronary intervention vs coronary artery bypass grafting for unprotected left main stenosis, a two-decade experience on the outcomes of mitral valve repair in ischemic mitral regurgitation, maternal, valvular and fetal outcomes of pregnancy following aortic valve replacement, and temporary mechanical circulatory support in left ventricular assist device candidates with right ventricular dysfunction. In addition, Joel explores if forgotten techniques of thoracoplasty with latissimus dorsi myoplasty are relevant today, the Nuss procedure after previous Ravitch operation, and uniportal VATS repair of traumatic right main bronchus transection following blunt chest injury. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Unprotected Left Main Stenosis: 10-Year Final Results From the Randomised, Open-Label, Non-Inferiority NOBLE Trial Outcomes of Mitral Valve Repair in Ischemic Mitral Regurgitation: A Two-Decade Experience Maternal, Valvular and Foetal Outcomes of Pregnancy Following Aortic Valve Replacement  Temporary Mechanical Circulatory Support in Left Ventricular Assist Device Candidates With Right Ventricular Dysfunction: Acuity Without Long-Term Futility CTSNet Content Mentioned Are the Forgotten Techniques of Thoracoplasty With Latissimus Dorsi Myoplasty Relevant Today?  Nuss Procedure After Previous Ravitch Operation  Uniportal VATS Repair of Traumatic Right Main Bronchus Transection Following Blunt Chest Injury  Other Items Mentioned The REPEAT Trial Career Center CTSNet Events Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

For decades, a tight carotid stenosis felt like a ticking time bomb — a plaque waiting to throw an embolus and cause the next stroke. We were taught that severe narrowing meant surgery, and trials like ACAS and ACST-1 seemed to prove it. But medicine has changed. Statins, antiplatelets, tighter blood pressure control, even PCSK9 and GLP-1 therapies have quietly slashed stroke risk, and now newer data from CREST-2 suggest that for many asymptomatic patients, the knife — or the stent — may not add much at all. So if modern medical therapy works better than ever… who actually benefits from intervention anymore? Today, we unpack the evidence, the controversies, and how to counsel the patient who feels perfectly fine but has high-grade stenosis.Hosts: Carolyn Judge, Andrew Huang, Luciano Delbono, Frank Davis, Robert BeaulieuInstitution: University of Michigan, Department of Surgery, Section of Vascular SurgeryLearning objectives: Describe how modern intensive medical therapy has transformed the natural history of asymptomatic carotid stenosis and explain why contemporary patients experience substantially lower annual stroke risk than those in earlier eras. Interpret and compare the results of landmark trials—including ACAS, ACST-1, and CREST-2—to assess the relative benefits of medical therapy, endarterectomy, and stenting. Apply current evidence and guideline recommendations to patient care by selecting which asymptomatic patients are most likely to benefit from carotid revascularization versus optimized medical therapy alone. References:SVS Guidelines:Brook, R. D., et al. (2022). Society for Vascular Surgery clinical practice guidelines for management of extracranial carotid artery disease. Journal of Vascular Surgery, 75(1), e1–e67. https://doi.org/10.1016/j.jvs.2021.09.031CREST (1)Brott, T. G., Hobson, R. W., Howard, G., et al. (2010). Stenting versus endarterectomy for treatment of carotid-artery stenosis. New England Journal of Medicine, 363(1), 11–23. https://doi.org/10.1056/NEJMoa0912321CREST-2Brott, T. G., Howard, G., Fong, P., et al. (2024). Randomized trial of carotid artery stenting or carotid endarterectomy vs best medical therapy for asymptomatic carotid stenosis: CREST-2 results. [Manuscript in preparation]. ClinicalTrials.gov Identifier: NCT02089217. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02089217ACST-1Halliday, A., Mansfield, A., Marro, J., et al. (2004). Randomised trial of carotid artery surgery for asymptomatic stenosis. Lancet, 363(9420), 1491–1502. https://doi.org/10.1016/S0140-6736(04)16153-1ACST-2Halliday, A., Bulbulia, R., Bonati, L. H., et al. (2021). Carotid artery stenting versus carotid endarterectomy in patients with asymptomatic carotid stenosis (ACST-2): A randomised trial. Lancet, 398(10291), 1065–1073. https://doi.org/10.1016/S0140-6736(21)01980-1ACASExecutive Committee for the Asymptomatic Carotid Atherosclerosis Study. (1995). Endarterectomy for asymptomatic carotid stenosis. JAMA, 273(18), 1421–1428. https://doi.org/10.1001/jama.1995.03520420033036Sponsor URL: https://www.goremedical.com/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In his weekly clinical update, Dr. Griffin and Vincent Racaniello note the uncertain future of the National Science Foundation amid shifting U.S. funding priorities and governance; the rise of China as a global research powerhouse; ongoing advances and controversies in vaccines shaped by the World Health Organization and the Centers for Disease Control and Prevention; vaccine policy battles in Florida; European approval of the moderna mCOMBRIAX, COVID-19 and influenza vaccine, the mounting evidence supporting preventive vaccination strategies including that for HPV and the HepB birth dose; the spread of drug-resistant infections and the resurgence of HIV in Zambia; and the enduring public trust in scientists despite political turbulence, before Dr. Griffin deep dives into the measles outbreak, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, the efficacy of the influenza vaccine for children, PEMGARDA authorized use for certain immunocompromised individuals where to find PEMGARDA, how to access and pay for Paxlovid, use of remdesivir for RSV, how administration of Paxlovid did not affect hospitalization of high-risk vaccinated patients, where to go for answers about long COVID-19, if SARS-CoV-2 infection may facilitate EBV reactivation, exercise for treating long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Entire NSF science advisory board fired by Trump administration (Nature) United States v. Arthrex, Inc.(Harvard Law Review) United States v. Arthrex Inc. [SCOTUSbrief] (Federalist Society) China could be the world's biggest public funder of science within two years (Nature) The Vaccine Skeptic in Trump's New C.D.C. Leadership Team (NY Times) World Immunization week: Largest catch-up initiative delivers over 100 million childhood vaccinations (WHO) Pigs are flying!: Florida Republicans refuse to take up DeSantis bill loosening vaccine mandates (NY Times) Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19(moderna) America First! AIDS Creeps Back in Parts of Zambia, a Year After U.S. Cuts to H.I.V. Assistance (NY Times) Emergence of Extensively Drug-Resistant Shigellosis — United States, 2011–2023 (CDC: MMWR) Scientists Esteemed by Public, with Vaccine Scientists Seen as Similar to Scientists in General (Annenberg: Public Policy Center, University of Pennsylvania) RFK Jr. is holding up $600M in vaccines for poor countries (Politico) Trump Withdraws Nomination of Casey Means for Surgeon General (NY Times) What? Benefit of preventive strategies like vaccination? Incidence of human papillomavirus infections in women aged 27 years and older in the US: A federated data network study (International Journal of Infectious Diseases) Economic Impact of Delaying the Infant Hepatitis B Vaccination Schedule (JAMA Pediatrics) Impact of Removing the Universal Hepatitis B Birth-Dose Vaccination in the US (JAMA Pediatrics) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Dangers of measles infection (NY Times) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (Xofluza) Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel — United States, 2024–25 Influenza Season (CDC: MMWR) Pediatric Vaccine Effectiveness Against Influenza Hospitalization And Outpatient Visits: 2021–2024 (Pediatrics) Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022–2024 (Pediatrics) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study (LANCET: Infectious Diseases) First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients (JID) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients(NEJM) Same Pill, Different Impact — Reassessing the Efficacy of Nirmatrelvir–Ritonavir(NEJM) Paxlovid doesn't reduce hospitalization, death rates in vaccinated high-risk COVID outpatients, trial shows (CIDRAP) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia: Columbia University Irving Medical Center) The answers: Long COVID Acute COVID-19 is associated with altered CD8 T-cells indicative of impaired ability to control Epstein–Barr virus reactivation (Medical Microbiology and Immunology) Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial (Journal of Cachexia, Sarcopenia and Muscle) Reaching out to US house representative Letters read on TWiV 1318 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Listener discretion is advised. References: Cook CE, Thigpen CA. Five good reasons to be disappointed with randomized trials. J Man Manip Ther. 2019 May;27(2):63-65. doi: 10.1080/10669817.2019.1589697. Epub 2019 Mar 14. PMID: 30935322 Fernainy P, Cohen AA, Murray E, Losina E, Lamontagne F, Sourial N. Rethinking the pros and cons of randomized controlled trials and observational studies in the era of big data and advanced methods: a panel discussion. BMC Proc. 2024 Jan 18;18(Suppl 2):1. doi: 10.1186/s12919-023-00285-8. Erratum in: BMC Proc. 2024 Aug 16;18(1):16. doi: 10.1186/s12919-024-00299-w. PMID: 38233894 Ramchurn TP, Nundy S. Randomised clinical trials in surgery: are we at a crossroads? Ann Med Surg (Lond). 2023 Nov 7;86(1):3-6. doi: 10.1097/MS9.0000000000001457. PMID: 38222736

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltextTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Die im Dezember 2025 publizierten Ergebnisse knüpfen an die bereits in der POM 8 (2021) diskutierten Konzepte der intensivierten Neoadjuvanz an und liefern wichtige neue Daten zur onkologischen Wirksamkeit. Darüber hinaus bietet die Studie zahlreiche Anknüpfungspunkte zur aktuellen Entwicklung, unter anderem im Kontext der erwarteten PROTEUS-Daten, laufender PSMA-PET-Studien (EAGLE-I) sowie neuer chirurgischer Navigationsansätze.

Send us a textDer Einsatz von Hydroxyethylstärke (HES) zur perioperativen Volumentherapie ist seit Jahren kontrovers diskutiert, insbesondere im Hinblick auf mögliche renale Risiken. In dieser Episode analysieren wir die PHOENICS-Studie, die größte randomisierte, doppelblinde Untersuchung zum Vergleich von 6 % HES 130/0.4 mit kristalloiden Lösungen im perioperativen Einsatz.Buhre W, Díaz-Cambronero O, Schaefer S, et al.Safety and efficacy of 6 % hydroxyethyl starch in patients undergoing major surgery: The randomised controlled PHOENICS trial.European Journal of Anaesthesiology. 2026;43:1–10.DOI: 10.1097/EJA.0000000000002307Die perioperative Volumentherapie ist ein zentraler Bestandteil der hämodynamischen Stabilisierung bei großen chirurgischen Eingriffen. Während Hydroxyethylstärke (HES) aufgrund seiner intravasalen Verweildauer effektiv zur Volumenexpansion eingesetzt wird, haben frühere Studien bei kritisch kranken und septischen Patient:innen Sicherheitsbedenken hinsichtlich renaler Komplikationen aufgeworfen.Die PHOENICS-Studie ist eine multizentrische, randomisierte, doppelblinde Phase-IV-Studie, in der 1958 Patient:innen (ASA II–III) mit erwarteten Blutverlusten ≥ 500 ml bei elektiver abdomineller Chirurgie entweder 6 % HES 130/0.4 oder eine balancierte kristalloide Lösung erhielten. Die Volumentherapie erfolgte leitliniengerecht und innerhalb der zugelassenen Dosierungsgrenzen. Primärer Endpunkt war die Veränderung der cystatin-C-basierten geschätzten glomerulären Filtrationsrate (eGFR) innerhalb der ersten drei postoperativen Tage. Ein zentraler sekundärer Endpunkt war ein kombinierter Endpunkt aus Mortalität und schweren postoperativen Komplikationen bis Tag 90.HES erwies sich im primären Endpunkt als nicht unterlegen gegenüber kristalloiden Lösungen hinsichtlich der Einschränkung der frühen postoperativen Nierenfunktion. Auch für den kombinierten Endpunkt aus Mortalität und schweren Komplikationen nach 90 Tagen konnte Nichtunterlegenheit gezeigt werden. Die Ein-Jahres-Nachbeobachtung ergab keine signifikanten Unterschiede bezüglich Gesamtmortalität oder Notwendigkeit einer Nierenersatztherapie. Darüber hinaus zeigten sich bei HES eine geringere positive Flüssigkeitsbilanz, eine geringere Abnahme des mittleren arteriellen Drucks sowie ein reduzierter Bedarf an vasoaktiven Substanzen.Die Ergebnisse der PHOENICS-Studie liefern robuste Evidenz dafür, dass der perioperative, indikationsgerechte Einsatz von 6 % HES 130/0.4 bei chirurgischen Patient:innen ohne Kontraindikationen gut verträglich ist und keine klinisch relevante Verschlechterung der Nierenfunktion oder der postoperativen Outcomes verursacht.

Nase zu, Geldbeutel auf! Bei Erkältung landet oft irgendwas aus der Apotheke im Einkaufskorb. Aber können Erkältungsmittel wie Gelomyrtol, ACC-Akut, Sinupret oder Dolo-Dobendan die Erkältung wirklich bekämpfen? Oder haben wir es hier hauptsächlich mit dem Placeboeffekt zu tun? Ein Blick in die Studienlage zeigt: Für viele Mittel ist die wissenschaftliche Evidenz überraschend dünn. Falls ihr in dieser Folge Umckaloabo, Meditonsin, Aspirin Complex und Wick MediNait vermisst – die haben wir uns in Folge #48 angeschaut: https://www.quarks.de/podcast/quarks-science-cops-folge-48-erkaeltungsmittel-wissenschaft-oder-kruemeltee/ Aus der Quarks-Redaktion empfehlen wir den Quarks-Podcast Mal Angenommen. Erste Folge: Mal angenommen, Deutschland wäre jung. Den gibt's hier: https://1.ard.de/quarks_mal_angenommen_audiothek und hier: https://1.ard.de/quarks_mal_angenommen_spotify Hier sind unsere wichtigsten Quellen für diese Folge (alle findet ihr auf https://www.quarks.de/podcast/erkaeltungsmittel-2-quarks-science-cops): Cardot, J.-M. et al.: Validated correlation of mass loss and drug release [...] cetylpyridinium chloride (CPC) and benzocaine (1.4 mg/10 mg) lozenges […] (Journal of Drug Delivery Science and Technology, 2022) https://www.sciencedirect.com/science/article/pii/S177322472200733X Jund, R. et al. Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis (Rhinology, 2012) https://www.rhinologyjournal.com/Rhinology_issues/1120.pdf S3-Leitlinie der DEGAM für Halsschmerzen von 2020 (aktuellste Fassung, wird aktuell überarbeitet) https://register.awmf.org/assets/guidelines/053-010l-S3_Halsschmerzen_2021-12-abgelaufen.pdf Jund, R. et al.: Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. (Acta Oto-Laryngologica, 2014) https://pubmed.ncbi.nlm.nih.gov/25496178/ Gillissen, A. et al.: A Multi-centre, Randomised, Double-blind, Placebo-controlled Clinical Trial on the Efficacy and Tolerability of GeloMyrtol® forte in Acute Bronchitis (Drug Research, 2013) https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0032-1331182 S3-Leitlinie DEGAM Akuter und chronischer Husten 2021 https://register.awmf.org/assets/guidelines/053-013l_S3_akuter-und-chronischer-Husten_2025-11.pdf Sheffner, A. L.: The Reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-Acetyl-Cysteine (Annals oft he New York Academy of Sciences, 1963) https://nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1749-6632.1963.tb16647.x Video- und Ton-Ausschnitte, die in dieser Episode verwendet wurden: Werbespot GeloMyrtol® forte https://www.youtube.com/watch?v=HABJPkjpQVk Werbespot ACC https://www.youtube.com/watch?v=5IYpoJc1MCk Werbespot ACC Akut mit Iris Berben https://www.youtube.com/watch?v=DYow3EZLIDQ Werbespot Dolo Dobendan https://www.facebook.com/DobendanDeutschland/videos/1945925302566218 Werbespot Sinupret eXtract https://www.youtube.com/watch?v=UYyKfa2rx2w Donald Trump speech from 2024 election night https://www.youtube.com/watch?v=vPOdsmGXUAM Von Maximilian Doeckel und Jonathan Focke.

Send us a textTreatment of Hypotension of Prematurity: a randomised trial.Alderliesten T, Arasteh E, van Alphen A, Groenendaal F, Dudink J, Benders MJ, van Bel F, Lemmers P. Arch Dis Child Fetal Neonatal Ed. 2025 Dec 15;111(1):F60-F66. doi: 10.1136/archdischild-2024-328253.PMID: 40413017 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

What really makes a cow go lame, and why did it take so long to change our minds? We sit down with Professor Jon Huxley—raised on a Welsh dairy, now leading Massey University's vet school in New Zealand—for a candid tour through research that reshaped mastitis control, lameness prevention, and fresh cow care.Jon shares the story behind teat sealants becoming a cornerstone of selective dry cow therapy, showing how solid trials helped cut antibiotic use without compromising udder health. We then tackle the big pivot in lameness thinking: moving beyond the old acidosis-laminitis narrative to the digital cushion, body condition, and the brutal role concrete plays in claw horn lesions. The result is a practical blueprint—protect condition around calving, improve surfaces and cow flow, and trim with function in mind.Treatment gets equal airtime. Randomised trials demonstrate why NSAIDs matter for lame cows, reducing inflammation and pain to speed recovery. Extend that approach to fresh heifers and the benefits often reach into second lactation. From there, we zoom out: are mastitis, metritis, ketosis, and lameness different faces of the same early lactation inflammatory stress? If the transition cow is the most fragile athlete on the farm, then feed space, comfort, calm routines, and energy balance are one system, not a checklist.We also compare UK housed systems with New Zealand's pasture-first dairying: longer walks on laneways, fewer hours on concrete, and lower lameness, but rising buffer feeding, new shelters, and tough conversations on nutrient leaching. Along the way, John explains how Massey's hands-on facilities and the Kiwi “give it a go” mindset produce work-ready vets who can turn evidence into action.Listen for clear, usable insights on mastitis prevention, lameness treatment, digital cushion management, underfoot design, and the transition period. If you want fewer sore feet, fewer sick fresh cows, and more sustainable milk, this conversation pulls the science onto the yard. Enjoy the ride—and if it helps, share it with a friend, subscribe, and leave a quick review to support the show.Send us a textFor more information about our podcast visit www.chewinthecud.com/podcast or follow us on Instagram @chewinthecudpodcast. ChewintheCud Ltd is also on Facebook & LinkedIn. You can email us directly at podcast@chewinthecud.com

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Christopher McGregor, professor in the Department of Surgery at the University of Minnesota Twin Cities, about the current state of cardiac and kidney xenotransplantation. Chapters 00:00 Intro  03:10 Sir Terence English  08:00 JANS 1, Cardiac Xenotransplantation  09:13 JANS 2, Coffee Consumption on AF  11:06 JANS 3, Environmental Factors Acute AD  12:49 JANS 4, PROTHOR Trial  15:15 Video 1, Combined AV & Coronary via LAM  17:08 Video 2, ARCA w MV Prolapse  19:32 Video 3, Redo Elephant Trunk After EAR  22:06 Chris McGregor Interview  48:23 Upcoming Events  50:15 Closing  They discussed the three approved trials for xenotransplantation in 2025, the preclinical efficacy assessment, and the various challenges of xenotransplantation. Additionally, they explored the history of orthotopic transplants, heart failure, and antibody-mediated rejection. They also examined the future of xenotransplantation and the anatomy of pig hearts vs human hearts.   Joel also highlights recent JANS articles on the status of cardiac xenotransplantation including preclinical models, the DECAF randomized clinical trial on if caffeinated coffee consumption or abstinence reduces atrial fibrillation; the impact of environmental factors on acute aortic dissection; and a multicenter, international, randomized, controlled, phase 3 trial on the effects of intraoperative higher vs lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR).   In addition, Joel explores combined aortic valve and coronary surgery via left anterior minithoracotomy, management of anomalous right coronary artery in a patient with mitral valve prolapse, and redo frozen elephant trunk after endovascular arch repair. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) 2025: Status of Cardiac Xenotransplantation Including Preclinical Models  2.) Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial  3.) Weathering the Aorta: The Impact of Environmental Factors on Acute Aortic Dissection   4.) Effects of Intraoperative Higher Versus Lower Positive End-Expiratory Pressure During One-Lung Ventilation for Thoracic Surgery on Postoperative Pulmonary Complications (PROTHOR): A Multicentre, International, Randomised, Controlled, Phase 3 Trial  CTSNet Content Mentioned  1.) Combined Aortic Valve and Coronary Surgery via Left Anterior Minithoracotomy: Clinical Experience With Sutureless Bioprosthesis  2.) Management of Anomalous Right Coronary Artery in a Patient With Mitral Valve Prolapse  3.) Redo Frozen Elephant Trunk After Endovascular Arch Repair  Other Items Mentioned  1.) Resident Video Competition  2.) 2025 CTSNet Recruitment Guide   3.) Career Center   4.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Did you know that a single crumb of bread is enough to cause an autoimmune response in children with celiac disease? Dr. Pankaj Vohra, Professor of Pediatrics and Board-Certified Pediatric Gastroenterologist, joins medical student Andrea Smith to discuss the evaluation and management of celiac disease, as well as essential guidance for following a gluten-free diet. Specifically, they will: Review the epidemiology of celiac disease and identify common symptoms and presentations of celiac disease Describe the pathophysiology of celiac disease including histopathological changes to the duodenum Identify diagnostic tests and criteria for diagnosing celiac disease in the pediatric population Identify common sources of gluten and the basics of identifying gluten on food labels Discuss typical management of celiac disease including appropriate screening tests and managing accidental gluten ingestion Special thanks to Dr. Rebecca Yang and Dr. Neeharika Bade for peer reviewing this episode. CME available free with sign up: Link coming soon! References: Bolia, R., & Thapar, N. (2023). Celiac Disease in Children: A 2023 Update. In Indian Journal of Pediatrics. Springer. https://doi.org/10.1007/s12098-023-04659-w Gidrewicz, D., Potter, K., Trevenen, C. L., Lyon, M., & Butzner, J. D. (2015). Evaluation of the ESPGHAN celiac guidelines in a North American pediatric population. American Journal of Gastroenterology, 110(5), 760–767. https://doi.org/10.1038/ajg.2015.87 Hill, I. D., Fasano, A., Guandalini, S., Hoffenberg, E., Levy, J., Reilly, N., & Verma, R. (2016). NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. Journal of Pediatric Gastroenterology and Nutrition, 63(1), 156–165. https://doi.org/10.1097/MPG.0000000000001216 Husby, S., Koletzko, S., Korponay-Szabó, I., Kurppa, K., Mearin, M. L., Ribes-Koninckx, C., Shamir, R., Troncone, R., Auricchio, R., Castillejo, G., Christensen, R., Dolinsek, J., Gillett, P., Hróbjartsson, A., Koltai, T., Maki, M., Nielsen, S. M., Popp, A., Størdal, K., … Wessels, M. (2020). European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. In Journal of Pediatric Gastroenterology and Nutrition (Vol. 70, Issue 1, pp. 141–156). Lippincott Williams and Wilkins. https://doi.org/10.1097/MPG.0000000000002497 Nenna, R., Tiberti, C., Petrarca, L., Lucantoni, F., Mennini, M., Luparia, R. P. L., Panimolle, F., Mastrogiorgio, G., Pietropaoli, N., Magliocca, F. M., & Bonamico, M. (2013). The celiac iceberg: Characterization of the disease in primary schoolchildren. Journal of Pediatric Gastroenterology and Nutrition, 56(4), 416–421. https://doi.org/10.1097/MPG.0b013e31827b7f64 Sahin, Y. (2021). Celiac disease in children: A review of the literature. In World Journal of Clinical Pediatrics (Vol. 10, Issue 4, pp. 53–71). Baishideng Publishing Group Co. https://doi.org/10.5409/wjcp.v10.i4.53 Salden, B. N., Monserrat, V., Troost, F. J., Bruins, M. J., Edens, L., Bartholomé, R., Haenen, G. R., Winkens, B., Koning, F., & Masclee, A. A. (2015). Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Alimentary Pharmacology and Therapeutics, 42(3), 273–285. https://doi.org/10.1111/apt.13266 Schuppan, D., Mäki, M., Lundin, K. E. A., Isola, J., Friesing-Sosnik, T., Taavela, J., Popp, A., Koskenpato, J., Langhorst, J., Hovde, Ø., Lähdeaho, M.-L., Fusco, S., Schumann, M., Török, H. P., Kupcinskas, J., Zopf, Y., Lohse, A. W., Scheinin, M., Kull, K., … Greinwald, R. (2021). A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New England Journal of Medicine, 385(1), 35–45. https://doi.org/10.1056/nejmoa2032441 Tack, G. J., van de Water, J. M. W., Bruins, M. J., Kooy-Winkelaar, E. M. C., van Bergen, J., Bonnet, P., Vreugdenhil, A. C. E., Korponay-Szabo, I., Edens, L., von Blomberg, B. M. E., Schreurs, M. W. J., Mulder, C. J., & Koning, F. (2013). Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study. World Journal of Gastroenterology, 19(35), 5837–5847. https://doi.org/10.3748/wjg.v19.i35.5837 Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54: 136–160

When first introducing new procedural skills, direct sensorimotor experience with guided support appears more beneficial than extended observation. Read the accompanying article here: https://doi.org/10.1111/medu.15725

Tom Lewis, DVM, DACVD is back on the podcast! Last year, Dr. Lewis joined the podcast last year to discuss the release of Zenrelia. One year later, he is back to discuss his experience with having this medication for a year and the relief it has provided for hundreds of his canine patients. Also, we discuss the recent change to the US boxed label warning which removed the vaccine induced disease portion of the label.Learn more on this week's episode of The Derm Vet podcast!Studies mentioned in podcast: Recent study regarding vaccine booster response in dogs receiving Zenrelia: Fent, G.M., Jacela, J., Plazola-Ortiz, R. et al. Immunologic response to first booster vaccination in dogs treated with zenrelia™ (ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls. BMC Vet Res 21, 481 (2025). https://doi.org/10.1186/s12917-025-04929-zRecent study regarding safety of Zenrelia: S. Forster, C. M. Trout, S. Despa, A. Boegel, D. Berger, and S. King, “ Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial,” Veterinary Dermatology (2025): 1–13, https://doi.org/10.1111/vde.70009.Timestamps00:00 Intro02:46 Zenrelia box label warning change08:14 What does the box label warning change mean and why it's only in the US?12:10 Looking at every patient as an individual17:00 How comfortable do you feel using Zenrelia long-term?22:14 Outro

Drs Joseph Mikhael and Saad Usmani discuss why quadruplet therapy is now the new standard of care for treating newly diagnosed multiple myeloma patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002714. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38084760/ Isatuximab, Lenalidomide, Dexamethasone and Bortezomib in Transplant-Ineligible Multiple Myeloma: The Randomized Phase 3 BENEFIT Trial https://pubmed.ncbi.nlm.nih.gov/38830994/ Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma: The Randomized Phase 3 CEPHEUS Trial https://pubmed.ncbi.nlm.nih.gov/39910273/ Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38832972/ A Phase 2 Study of Modified Lenalidomide, Bortezomib and Dexamethasone in Transplant-Ineligible Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/29740809/ Bortezomib With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients With Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/28017406/ Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial https://pubmed.ncbi.nlm.nih.gov/32325490/ Carfilzomib Induction, Consolidation, and Maintenance With or Without Autologous Stem-Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: Pre-Planned Cytogenetic Subgroup Analysis of the Randomised, Phase 2 FORTE Trial https://pubmed.ncbi.nlm.nih.gov/36528035/ Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients https://www.sciencedirect.com/science/article/abs/pii/S0006497123735416

We're witnessing the early stages of a paradigm shift, as artificial intelligence is beginning to impact virtually every aspect of healthcare, from research to patient care. And there's much, much more to come.    This week, Dr. Brad Willingham, the Director of MS Research at Shepherd Center in Atlanta, joins me to discuss how AI will impact MS patient care. We'll also share the encouraging results from a Phase 2 open-label extension study for Fenebrutinib, an investigational disease-modifying therapy. We'll tell you about study results that show exercise interventions that follow physical activity guidelines for MS can have a significant impact on MS-related depression. And we're sharing the results of a study that illustrate what can happen when you delay starting a disease-modifying therapy. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: How AI will impact MS patient care  :22 Fenebrutinib shows positive results after one-year extension study  1:33 MS-related depression can be significantly eased through exercise intervention that follows physical activity guidelines for MS  3:36 What happens when you delay starting disease-modifying therapy?   8:46 Dr. Brad Willingham discusses how artificial intelligence is impacting all aspects of healthcare  14:29 Share this episode  33:18 Have you downloaded the free RealTalk MS app?  33:38 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/413 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Become an MS Activist https://nationalmssociety.org/advocacy STUDY: Safety and Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (FENopta): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial and Open-Label Extension https://thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/abstract?rss=yes STUDY: Effects of Meeting Exercise Guidelines on Depression and Anxiety in Multiple Sclerosis: A Systematic Review and Meta-Analysis https://tandfonline.com/doi/full/10.1080/09593985.2025.2518261 Exercise and Physical Activity Recommendations for ALL People with MS  https://nationalmssociety.org/news-and-magazine/news/exercise-and-physical-activity-recommend STUDY: Delayed Access and Adherence are Real-World Challenges That Compromise Effectiveness of Natalizumab in Multiple Sclerosis https://sciencedirect.com/science/article/abs/pii/S2211034825003694 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 413 Guest: Dr. Brad Willingham Privacy Policy

In today's episode, Arlo, Kess and Jacob's randomised characters continue their tour through the Hall of Electric Curiosity.Connect:⁠⁠⁠Sounds Like Adventure on Twitch⁠⁠⁠ ⁠⁠⁠Sounds Like Adventure on YouTube⁠⁠⁠⁠⁠⁠Sounds Like Adventure on Instagram⁠⁠⁠⁠⁠⁠Sounds Like Adventure on Threads

The Midnight GlacierDrop is finally here, and in this episode, I break down everything you need to know about claiming your NIGHT tokens.Midnight is a new privacy-focused blockchain built by IOG, featuring two key tokens: NIGHT (a utility and governance token) and DUST (a non-transferable shielded resource for private transactions).This episode walks through the entire claim and redemption process, eligibility requirements, and why the staggered release of NIGHT is designed to prevent token dumping. The GlacierDrop claim is open to holders of ADA, BTC, ETH, XRP, BNB, SOL, AVAX, and BAT based on a snapshot taken on June 11, 2025. ADA holders receive the largest allocation—50% of the eligible airdrop supply. You'll need to connect your wallet to the official GlacierDrop portal when it launches and claim within a 60-day window.After that, unclaimed tokens move to the Scavenger Mine phase, followed by a long-term Lost & Found period that spans four years. Redemption of NIGHT tokens follows a 360-day vesting schedule with unlocks every 90 days, starting randomly within the first 90 days post-claim.Each redemption requires a transaction on Cardano, so be ready to cover network fees.Also, Cardano SPOs can earn NIGHT by participating in Midnight's block production. Delegators to those pools will benefit too—so be sure to speak with your SPO. 

We're back from our mid-season break! But we had some technical dramas that made it so we weren't all able to record in time for the new episode. So that means we'll be back with a new main Sounds Like Adventure campaign episode on the 8th of July.But to keep you company while you wait, we have two very special bonus episodes over the next two weeks. Join Jack, Arlo, Kess and Jacob as they get into one of the most chaotic D&D sessions in Sounds Like Adventure history. It's D&D but the characters are randomised.Connect:⁠⁠Sounds Like Adventure on Twitch⁠⁠ ⁠⁠Sounds Like Adventure on YouTube⁠⁠⁠⁠Sounds Like Adventure on Instagram⁠⁠⁠⁠Sounds Like Adventure on Threads

Send us a textEffects of liberal versus restrictive transfusion strategies on intermittent hypoxaemia in extremely low birthweight infants: secondary analyses of the ETTNO randomised controlled trial.Franz AR, Engel C, Bassler D, Rüdiger M, Thome UH, Maier RF, Krägeloh-Mann I, Essers J, Bührer C, Bittrich HJ, Roll C, Höhn T, Ehrhardt H, Boettger R, Körner HT, Stein A, Neuberger P, Henriksen TB, Greisen G, Poets CF; ETTNO Investigators.Arch Dis Child Fetal Neonatal Ed. 2025 Mar 26:fetalneonatal-2024-327643. doi: 10.1136/archdischild-2024-327643. Online ahead of print.PMID: 40139741As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textAzithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial.Lowe J, Gillespie D, Aboklaish A, Lau TMM, Consoli C, Babu M, Goddard M, Hood K, Klein N, Thomas-Jones E, Turner M, Hubbard M, Marchesi J, Berrington J, Kotecha S.Lancet Respir Med. 2024 Aug;12(8):608-618. doi: 10.1016/S2213-2600(24)00079-1. Epub 2024 Apr 25.PMID: 38679042 Free article. Clinical Trial. As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In his weekly clinical update, Dr. Griffin with Vincent Racaniello rue about the continuation of the gutting of the American public health infrastructure, the continuing measles outbreak, an unreported outbreak of deadly E.coli human infections, meningococcal disease before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections, the WasterwaterScan dashboard, ACIP recommended changes in guidelines for the RSV and COVID-19 vaccines, reactogenicity differences between Novavax and Pfizer COVID-19 vaccines, where to find PEMGARDA, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, long COVID interventions, effects of long COVID in children and adolescents and a list of ongoing clinical trials for long COVID treatment. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Making America Healthy Again-purging of administrators at HHS (Politico) Making America Healthy Again-purging of data (Politico) Deep cuts of the federal government (NY Times) Cutting NIH, CDC and HHS promotes chronic disease research(Washington Post) Political ideology and trust in scientists in the USA(Nature Human Behavior) US political conservatives have deep, unbudging suspicion of science, survey suggests(CIDRAP) A deadly E. coli outbreak hit 15 states, but the FDA chose not to publicize it(NBC News) Invasive meningococcal disease – Kingdom of Saudi Arabia(WHO) The essential guide to understanding the differences between hajj and umrah (Marhabahaji) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Measles booster? (Washington Post) How to stop an outbreak…….fire the experts (Washington Post) Measles cases and outbreaks (CDC Rubeola) Measles 159 in Texas…. (Texas Health and Human Services) 2025 Measles outbreak guidance (New Mexico Health) Measles and rubella weekly monitoring (Government of Canada) Measles vaccine recommendations from NYP (jpg) NAFMA: North American Free Measles agreement…..(NY Times) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Doctors' talk measles (YouTube) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) 200 children die from flu (CIDRAP) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) ACIP votes to expand recommendation for Pfizer'sRSV vaccine Abrysvo® to include adults aged 50 to 59 at increased risk of disease (Pfizer) Respiratory syncytial virus and incidence of cardiovascular events: a nationwide self-controlled case series analysis (JACC Journals) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Comorbidities associated with different degrees of severity in children and young people hospitalized with acute COVID-19 (Pediatric Infectious Disease Journal) SHIELD-Utah study shows Novavax's COVID-19 vaccine induces lower reactogenicity symptoms compared to mRNA (Novavax) Interim clinical considerations for use of COVID-19 vaccines in the United States (CDC Vaccines & Immunizations) Novavax says its COVID vaccine produces fewer, milder reactions than Pfizer version(CIDRAP) US CDC advisers discuss narrower use of COVID-19 vaccines (Reuters) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Kidney Function following COVID-19 in children and adolescents(JAMA Network Open) Cardiovascular post-acute sequelae of SARS-CoV-2 in children and adolescents: cohort study using electronic health records(Nature Communications) Great barrington declaration (gbdeclaration.org) Clinical trials: Effectiveness of transcranial direct current in patients with persistent COVID-19 with headaches and chronic pain. Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC) Acupuncture for post COVID-19 Condition (Long COVID) neuropsychiatric symptoms Pain relief with integrative medicine (prime)?: feasibility of acupuncture for long COVID Electro-acupuncture for long COVID neuropsychiatric symptoms Randomised study to investigate the effectiveness of acupuncture for the relief of long COIVD-19 related fatigue (ACU-COVID) Vagus stimulation in female long COVID patients.(Vagus) Stellate ganglion block with lidocaine for the treatment of COVID-19-induced parosmia (Stella) Therapeutic updates on long COVID: Where things stand 5 years later (ID Society) Reaching out to US house representative Letters read on TWiV 1210 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

There's a range of different interventions at your disposal when managing spine pain. Today we're focusing on spinal manipulative therapy, and asking questions like: does it matter how you apply a manipulation to get the best outcomes for the patient? Answering the questions is Dr Casper Nim from the University of Southern Denmark. Casper is an Associate Professor, chiropractor, and senior researcher at the Spine Centre of Southern Denmark. ------------------------------ RESOURCES Does it matter how you apply spinal manipulative therapy? Network meta-analysis: https://www.jospt.org/doi/10.2519/jospt.2025.12707 Does targeting a specific vertebral level make a difference? Systematic review: https://www.jospt.org/doi/10.2519/jospt.2023.11962 Effect on clinical outcomes when targeting spinal manipulative therapy. Randomised controlled trial: https://pubmed.ncbi.nlm.nih.gov/32884045/ Preference randomised trials: https://www.jospt.org/doi/10.2519/josptmethods.2025.0129 JOSPT Methods journal website: https://www.jospt.org/toc/jospt-methods/current

Join us as we discuss effective non-diet focused methods for IBS relief. In this episode, Kate and Dr. Riehl review key factors on how gender can influence common symptoms of IBS.Hormones significantly influence IBS symptoms, with women being diagnosed 2.5 times more often than men, in part due to differences in gut function and pain perception. This episode features the following key discussion areas:• Women's fluctuating estrogen and progesterone levels affect gut motility and pain sensitivity throughout the menstrual cycle• Visceral hypersensitivity causes normal digestive sensations to be interpreted as pain - like a car alarm going off unnecessarily• The "microgenderome" refers to gender differences in gut microbiome that may contribute to women's higher rates of IBS and autoimmune conditions• Gut-directed hypnotherapy helps reprogram the subconscious mind to interpret gut sensations more accurately, with 70-80% improvement rates• Pelvic floor physical therapy can help address muscle tension that contributes to both constipation and diarrhea symptoms• Non-diet approaches including medications, supplements like enteric-coated peppermint, and lifestyle factors are effective IBS management tools• Regular exercise (especially in nature), adequate sleep, and stress management techniques complement other treatmentsFor more information on IBS-C treatments, check out our dedicated three-part series in episodes 14, 15, and 16.This podcast has been sponsored by Ardelyx and Nerva by Mindset Health.References:Mulak A, Taché Y, Larauche M. Sex hormones in the modulation of irritable bowel syndrome. World J Gastroenterol. 2014;20(10):2433-2448. doi:10.3748/wjg.v20.i10.2433Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology. 2002;123(5):1686-1701. doi:10.1053/gast.2002.36603Houghton LA, Jackson NA, Whorwell PJ, Morris J. Do male sex hormones protect from irritable bowel syndrome?. Am J Gastroenterol. 2000;95(9):2296-2300. doi:10.1111/j.1572-0241.2000.02314.xPeters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(5):447-459. doi:10.1111/apt.13706Learn more about Kate and Dr. Riehl:Website: www.katescarlata.com and www.drriehl.comInstagram: @katescarlata @drriehl and @theguthealthpodcastOrder Kate and Dr. Riehl's book, Mind Your Gut: The Science-Based, Whole-body Guide to Living Well with IBS. The information included in this podcast is not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider before starting any new treatment or making changes to existing treatment.

As part of the March issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews Associate Editor Yet Khor about the generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis.

Randomized Comparison Trial of Rehabilitation Very Early for Infants with Congenital HemiplegiaRoslyn N Boyd, Susan Greaves, Jenny Ziviani, Iona Novak, Nadia Badawi, Kerstin Pannek, Catherine Elliott, Margaret Wallen, Catherine Morgan, Jane Valentine, Lisa Findlay, Andrea Guzzetta, Koa Whittingham, Robert S Ware, Simona Fiori, Nathalie L Maitre, Jill Heathcock, Kimberley Scott, Ann-Christin Eliasson, Leanne SakzewskiPMID: 39477009 DOI: 10.1016/j.jpeds.2024.114381Free articleAbstractObjective: To compare efficacy of constraint-induced movement therapy (Baby-CIMT) with bimanual therapy (Baby-BIM) in infants at high risk of unilateral cerebral palsy.Study design: This was a single-blind, randomized-comparison-trial that had the following inclusion criteria: (1) asymmetric brain lesion (2) absent fidgety General Movements, (3) Hammersmith Infant Neurological Examination below cerebral palsy cut-points, (4) entry at 3-9 months of corrected age, and (5) greater than 3-point difference between hands on Hand Assessment Infants (HAI). Infants were randomized to Baby-CIMT or Baby-BIM, which comprised 6-9 months of home-based intervention. Daily dose varied from 20 to 40 minutes according to age (total 70-89.2 hours). Primary outcome measure was the HAI after intervention, with secondary outcomes Mini-Assisting Hand Assessment and Bayley III cognition at 24 months of corrected age.Results: In total, 96 infants (51 male, 52 right hemiplegia) born median at 37-weeks of gestation were randomized to Baby-CIMT (n = 46) or Baby-BIM (n = 50) and commenced intervention at a mean 6.5 (SD 1.6) months corrected age. There were no between group differences immediately after intervention on HAI (mean difference MD 0.98 HAI units, 95% CI 0.94-2.91; P = .31). Both groups demonstrated significant clinically important improvements from baseline to after intervention (Baby-BIM MD 3.48, 95% CI 2.09-4.87; Baby-CIMT MD 4.42, 95% CI 3.07-5.77). At 24 months, 64 infants were diagnosed with unilateral cerebral palsy (35 Baby-CIMT, 29 Baby-BIM). Infants who entered the study between 3 and 6 months of corrected age had greater change in HAI Both Hands Sum Score compared with those who entered at ≥6 months of corrected age (MD 7.17, 95% CI 2.93-11.41, P = .001).Conclusions: Baby-CIMT was not superior to Baby-BIM, and both interventions improved hand development. Infants commencing intervention at greater than 6 months corrected age had greater improvements in hand function.https://pubmed.ncbi.nlm.nih.gov/39477009/

Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Admission to the intensive care unit (ICU) can be a challenging experience for patients and their families. Psychological burdens, including symptoms of anxiety, depression and post-traumatic stress, are among the most reported during the ICU stay.A recent study has been carried out as a joint project between France and the United States in which the experts have designed an intervention to improve outcomes for patients' families. For this intervention, they evaluated the nurse facilitator to support, model and teach communication strategies that will help in securing care aligned with patients' goals at the ICU. To learn more about this intervention, we interviewed one of the main authors, Nancy Kentish Barnes. Listen to our podcast for deeper insights into this study!

If you're looking to heal leaky gut and to strengthen your gut lining, there are a couple of different components to consider. Luckily, we have a new, science-based supplement that provides several lines of defense for your gut health. In this episode, I'll explain the best nutrients for your gut lining, and why Gut Rebuild Nutrients is the perfect all-around supplement for healing. 

An exciting new study finds that these herbal treatments and probiotics are very effective in healing SIBO! In this episode,I'll break down the study and provide the best protocol for approaching SIBO naturally. Watch now!  

We hear a lot about healing leaky gut, but how do we know we have it in the first place? Is a stool test enough? In this episode, I'll review the most effective and least effective leaky gut tests. Let's get the most accurate results, so you can move closer to healing! Watch now.   

Dr. Lacey Shiue, emergency ultrasound faculty, sits down with Alex and Venk to talk through ultrasound guided nerve blocks and plane blocks. We talk through key differences in commonly used medications, how to manage toxicity from those medications as well as a detailed discussion of several different specific blocks including: Erector Spinae Plane Block, Fascia Iliaca Compartment Block, Supraclavicular Block, Interscalene Block among others. In addition, she discusses the keys to advancing an emergency regional anesthesia program.   CONTACTS X - @AlwaysOnEM; @VenkBellamkonda YouTube - @AlwaysOnEM; @VenkBellamkonda Instagram – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch Email - AlwaysOnEM@gmail.com   RESOURCES FOR PRACTICE: MDCALC for anesthetic dose calculation: https://www.mdcalc.com/calc/10205/local-anesthetic-dosing-calculator  Safe Local app for anesthetic dose calculation: https://apps.apple.com/us/app/safelocal/id1440999841  New York School of Regional Anesthesia: https://www.nysora.com/filter-topics/  Highland County Emergency Medicine Website: https://highlandultrasound.com/  ASRA - American Society of Regional Anesthesia - Checklist for treatment of LAST: https://www.asra.com/news-publications/asra-updates/blog-landing/guidelines/2020/11/01/checklist-for-treatment-of-local-anesthetic-systemic-toxicity    REFERENCES: American College of Emergency Physicians Policy Statements: Ultrasound-Guided Nerve Blocks, published April 2021. Document accessed June 20, 2024 via: https://www.acep.org/patient-care/policy-statements/ultrasound-guided-nerve-blocks American College of Emergency Physicians Policy Statements: Guideline for ultrasound transducer cleaning and disinfection, approved April 2021. Document accessed June 20, 2024 via: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.acep.org/siteassets/new-pdfs/policy-statements/guideline-for-ultrasound-transducer-cleaning-and-disinfection.pdf  Disinfection of Ultrasound Transducers Used for Percutaneous Procedures: Intersocietal Position Statement. J Ultrasound Med. 2020; online before print. https://doi.org/10.1002/jum.15653  Ramesh S, Ayyan SM, Rath DP,Sadanandan DM. Efficacy and safety of ultrasound-guidederector spinae plane block compared to sham procedure inadult patients with rib fractures presenting to the emergencydepartment: A randomized controlled trial. Acad Emerg Med.2024;31:316-325. doi:10.1111/acem.14820 New York School of Regional Anesthesia: Ultrasound-guided fascia iliaca nerve block. Accessed June 21, 2024 via: https://www.nysora.com/techniques/lower-extremity/ultrasound-guided-fascia-iliaca-block/  Downs T, Jacquet J, Disch J, Kolodychuk N, Talmage L, Krizo J, Simon EL, Meehan A, Stenberg R. Large Scale implementation of fascia iliaca compartment blocks in an emergency department. West J Emerg Med. 2023 May 3;24(3):384-389 Makkar JK, Singh NP, Bhatia N, Samra T, Singh PM. Fascia iliaca block for hip fractures in the emergency department: meta-analysis with trial sequential analysis. Am J Emerg Med. 2021 Dec:50:654-660 Rukerd MRZ, Erfaniparsa L, Movahedi M, et al. Ultrasound-guided femoral nerve block versus fascia iliaca compartment block for femoral fractures in emergency department: a randomized controlled trial. Acute Med Surg. 2024 Mar 6;11(1):e936 Beaudoin FL, Haran JP, Liebmann O. A comparison of ultrasound-guided three-in one femoral nerve block versus parenteral opioids alone for analgesia in emergency department patients with hip fractures: a randomized controlled trial. Acad Emerg Med. 2013 Jun;20(6):584-91 Reavley P, Montgomery AA, Smith JE, Binks S, Edwards J, Elder G, Benger J. Randomised trial of the fascia iliaca block versus the 3-in-1 block for femoral neck fractures in the emergency department. Emerg Med J. 2015;32:685-689 Schulte SS, Fernandez I, Van Tienderen R, Reich MS, Adler A, Nguyen MP. Impact of the fascia iliaca block on pain, opioid consumption, and ambulation for patients with hip fractures: a prospective, randomized study. J Orthop Trauma. 2020 Oct;34(10):533-538   WANT TO WORK AT MAYO? EM Physicians: https://jobs.mayoclinic.org/emergencymedicine EM NP PAs: https://jobs.mayoclinic.org/em-nppa-jobs   Nursing/Techs/PAC: https://jobs.mayoclinic.org/Nursing-Emergency-Medicine EMTs/Paramedics: https://jobs.mayoclinic.org/ambulanceservice All groups above combined into one link: https://jobs.mayoclinic.org/EM-Jobs  

Essa foi uma semana de recomeços para quem vive no RS. Apesar do barulho dos helicópteros em alguns momentos do episódio, estamos retornando com os nossos programas regulares. Neste episódio do Journal Club, trazemos os seguintes artigos para vocês:1.     Neurodevelopmental Outcomes of Extremely Preterm Infants Fed Donor Milk or Preterm Infant Formula A Randomized Clinical Trial - Resultados do Neurodesenvolvimento de Prematuros Extremos Alimentados com Leite Humano de Banco ou Fórmula de Prematuro - Um Ensaio Clínico RandomizadoExiste diferenças em relação ao neurodesenvolvimento com dois anos de idade, quando comparamos uso de leite humano de banco e fórmula para prematuros?Descubra em: https://jamanetwork.com/journals/jama/article-abstract/2814657?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2023.27693 2.     Dextrose gel prophylaxis for neonatal hypoglycaemia and neurocognitive function at early school age: a randomised dosage trial - Profilaxia com gel de dextrose para hipoglicemia neonatal e função neurocognitiva em idade escolar precoce: um ensaio clínico randomizado O uso da profilaxia para hipoglicemia utilizando gel de dextrose é capaz de reduzir prejuízos ao desenvolvimento neuropsicomotor?Disponível em: https://fn.bmj.com/content/early/2024/02/12/archdischild-2023-3264523.     Effect of human milk-based fortification in extremely preterm infants fed exclusively with breast milk: a randomized controlled trial - Efeito da fortificação à base de leite humano em prematuros extremos alimentados exclusivamente com leite materno: ensaio clínico randomizado e controladoVale a pena investir no fortificante de leite materno a base de leite humano? Descubra em: https://www.thelancet.com/action/showPdf?pii=S2589-5370%2823%2900552-7 4.     Randomised study of a new inline respiratory function monitor (Juno) to improve mask seal and delivered ventilation with neonatal manikins - Estudo randomizado de um novo monitor de função respiratória (Juno) para melhorar a vedação da máscara e a ventilação em manequins neonataisQue a vedação da máscara é importante para a eficácia da VPP na reanimação neonatal não há dúvidas. Esse artigo mostra formas de detectar a vedação e corrigir a técnica em manequins. Disponível em: https://fn.bmj.com/content/early/2024/02/09/archdischild-2023-326256  Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Se estiver gostando do nosso Podcast, por favor deixe sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

Leaky gut can't be fixed by diet alone! Gut health is largely affected by a combination of your lifestyle habits and nutrition. If you want to heal a leaky gut, It's important to do these three things DAILY. Watch now! 

Dr. Natalie Scheeler, a naturopathic doctor specializing in integrative treatments for gastrointestinal conditions, shares her perspective and valuable insights on gut health. She discusses the difference between naturopathic doctors and traditional MDs, the use of fecal microbiota transplant (FMT) and Helminthic therapies in treating inflammatory bowel disease (IBD), the impact of food and probiotics on IBD, and trends in flare management and remission. Dr. Scheeler also provides information about her practice, Modrn Med, and offers a final message of hope and encouragement for patients seeking alternative or complementary treatment options. Takeaways Naturopathic doctors focus on preventative medicine and finding the root cause through a whole person approach using integrative treatments that can be used alongside conventional therapies. Fecal microbiota transplant (FMT) and Helminthic therapies are alternative treatments for IBD that show promise in inducing remission and maintaining gut health. Diet plays a significant role in creating a diverse microbiome. Modrn Med is an integrative and functional medicine practice that offers telehealth consultations and works in collaboration with other healthcare providers. There are other treatment options available for patients who have not found success with conventional therapies, and it is important to work with a knowledgeable practitioner to explore these options. Topics covered in the interview Difference Between Naturopathic Doctors (ND) and traditional doctors (MD or DO) Integrative Treatments for Gastrointestinal Conditions Fecal Microbiota Transplant (FMT) Impact of Food and Probiotics on IBD Trends in Flare Management and Remission Helminthic Therapies About Modrn Med From the show Stephanie: What are some of the trends that you've seen with helping people to get out of a flare and into remission? Dr. Scheeler: …the dietary aspect is a large trend I'm seeing I think, too, with social media. There's just the ability to spread so much information and so that is oftentimes how people coming into our office and have said, ‘I've tried these diets' or ‘I've done these diets' versus us kind of introducing them to that idea. So that's interesting. The other one is an herb called Qing Dai. It's a Chinese herb…which is an herb that can be really helpful for inducing remission, typically. We usually reserve it for remission induction versus maintenance therapy because there are some safety risks to that…I would always, always recommend working with a provider who's familiar with that herb…something that is important to say is that natural medicine isn't always safer, and it isn't always safe in general. There is risks associated with any treatments that you do. And so knowing those risks, having somebody who is familiar with those risks is important, especially if you are on the kind of quote-unquote conventional medications and add this stuff in, there could be interactions. Stephanie: Can you talk a little bit about the Modrn Med practice and what types of patients you see? Dr. Scheeler: Yeah, so ModernMed, we are a practice, we are all naturopathic doctors. There's four of us there. And we do integrative and functional medicine. A large part of our practice is gastrointestinal disease, including inflammatory bowel disease. I personally see patients exclusively via telehealth…but there is a location in LA, too, if people are interested. With that, since I do telehealth, I'm licensed in California, Arizona, Maryland, Vermont, and Connecticut, as of now. But all of us depending can either see you as patient if we're licensed in that state or do what we consider educational consults. So with patients who live out of state, we can share some of this information with you and help you do things safely or talk with your provider too…it's very common for us to work with other providers, especially myself working with gastroenterologists. I think when we all work as a team is when we get the best outcomes. And so patients, who may be in a state that we're not licensed in, we're comfortable talking to providers and usually there's no issues with that as long as we explain what we're doing. We always do evidence-based medicine. So as long as we share, even if they're not familiar with it off the bat, most people are open to working together and helping the patient out. Links and studies from the show Modern Med: https://www.modrnmed.com/dr-natalie-scheeler FMT for UC: Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1-10. doi:10.1007/s12328-017-0813-5 (PMID: 29285689)  FMT for CD: Zhou S, Cui Y, Zhang Y, Zhao T, Cong J. Fecal microbiota transplantation for induction of remission in Crohn's disease: a systematic review and meta-analysis. Int J Colorectal Dis. 2023;38(1):62. Published 2023 Mar 8. doi:10.1007/s00384-023-04354-4 (PMID: 36882658)  Helminthic Therapy in CD (Trichuris suis specific): Schölmerich J, Fellermann K, Seibold FW, et al. A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease. J Crohns Colitis. 2017;11(4):390-399. doi:10.1093/ecco-jcc/jjw184 (PMID: 27707789)  Helminthic Therapy in CD (Trichuris suis specific):  Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2014;2014(1):CD009400. Published 2014 Jan 20. doi:10.1002/14651858.CD009400.pub2 (PMID: 24442917)  Paper co-written by Dr. Scheeler on Qing Dai (Pronounced "Ching Dye") a.k.a. Indigo Naturalis: https://www.naturalmedicinejournal.com/journal/clinical-application-of-indigo-naturalis Support the podcast ❤️ at https://www.crohnsfitnessfood.com Get your copy of Crohn's Fitness Food and My Rocky Road to Health, Shop my favorite products, Read my favorite books, Subscribe to the podcast, Send a little love/coffee

Leaky gut can get better or worse depending on your diet and health routine. I'll break down how some foods can affect your gut health, and what to incorporate into your diet in order to heal. 

Join Professor Peter Nash from the Griffith University in Brisbane, and Maria Antonietta D'Agostino, the Head of the Rheumatology Department at the Catholic University of the Sacred Heart in Rome, as they discuss her recent paper 'Effects of Secukinumab on Synovitis and Enthesitis in Patients with Psoriatic Arthritis: 52-week Clinical and Ultrasound Results from the Randomised, Double-blind ULTIMATE Trial with Open Label Extension'.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: October 11, 2018 As the name suggests, "evidence-based medicine" is dependent on published evidence to support our clinical practice and medical decision-making. Implicit in this is the notion that all published evidence reflects the truth that underlies the biology, pathophysiology, and pharmacology of our health. This is not the case. Clinical research and published findings can be extremely limited, and what you read in Lancet and NEJM should be interpreted with caution. In this week's episode of the "I wonder" series, where Jim Siegler speaks with Ali Hamedani on various topics in medicine and neurology, the speakers review the major biases inherent to the practice and interpretation of clinical research. Produced by James E Siegler. Music by Jahzzar, Kai Engel, and Lee Rosevere. Sound effects by Mike Koenig, Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. REFERENCES Anonymous. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607):349-60. PMID 2899772Kazui H, Miyajima M, Mori E, Ishikawa M; SINPHONI-2 Investigators. Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2): an open-label randomised trial. Lancet Neurol 2015;14(6):585-94. PMID 25934242Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376(3):209-20. PMID 28002688Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003;327(7429):1459-61. PMID 14684649 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Pre-Hospital Rule-Out of Non-ST-Segment Elevation Acute Coronary Syndrome by a Single Troponin Measurement: Final One-Year Outcomes of the ARTICA Randomised Trial (AHA 2023)

Sustained inflation and chest compression versus 3:1 chest compression to ventilation ratio during cardiopulmonary resuscitation of asphyxiated newborns (SURV1VE): A cluster randomised controlled trial.Schmölzer GM, Pichler G, Solevåg AL, Law BHY, Mitra S, Wagner M, Pfurtscheller D, Yaskina M, Cheung PY; SURV1VE- Trial Investigators.Arch Dis Child Fetal Neonatal Ed. 2024 Jan 11:fetalneonatal-2023-326383. doi: 10.1136/archdischild-2023-326383. Online ahead of print.PMID: 38212104 As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

A new study entitled, “The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial” aimed to evaluate the effectiveness of a signaling lipid called Palmitoylethanolamide (PEA) in reducing the occurrence, duration, and severity of upper respiratory tract infections(URTIs). The results showed that participants who took PEA experienced fewer URTI episodes and had reduced symptoms compared to those who took a placebo, suggesting that PEA may be a safe and effective treatment option for URTIs. Palmitoylethanolamide (PEA) is a lipid compound that belongs to the N-acylethanolamine (NAE) family and has similar properties to endocannabinoids. In the context of cold and flu infections, PEA is suggested to regulate interleukins and inhibit mast cell production, thereby reducing inflammation. PEA activates NF-κB pathways through peroxisome proliferator-activated receptors (PPAR), particularly PPAR-α, and concentration-dependent mechanisms to decrease NLRP3 and inflammasome activation, ultimately leading to a decrease in the expression of cytokines and alleviation of upper respiratory tract infection symptoms. It is worth noting that the natural levels of PEA in the body and the use of PEA supplements have been found to be ineffective in producing significant clinical results due to poor absorption, resulting in low levels of PEA in the bloodstream. However, when PEA is combined with dispersion technology, such as Levagen+, the absorption of PEA is greatly improved, leading to higher concentrations in the bloodstream, which may enable a therapeutic effect. This study was conducted over a period of 12 weeks. It was a double-blind, randomized, placebo-controlled trial, where participants were divided into two groups: an active group receiving 300 mg of Levagen+ PEA twice a day and a placebo group receiving maltodextrin. The purpose of the study was to investigate the efficacy of Levagen+ PEA compared to the placebo in terms of the incidence, severity, and duration of upper respiratory tract infections (URTI).   During the study, 87 participants out of the total enrolled experienced at least one URTI, resulting in a total of 103 URTI episodes. The group receiving Levagen+ PEA reported significantly fewer URTI episodes (39) compared to the placebo group (64), and a lower number of participants who fell sick at least once during the study (32 vs. 55) when compared to the placebo group. Participants in the Levagen+ PEA group reported a significantly lower severity score for scratchy throat and cough. Overall, compliance with the study was high for both groups in terms of capsule consumption. The findings of the study indicate that individuals in the Levagen+ PEA group had a significantly lower number of upper respiratory tract infection (URTI) episodes compared to the placebo group. The study suggests that Levagen+ PEA could be a viable treatment for preventing upper respiratory tract infections (URTIs) and alleviating symptoms of cold and flu. The findings indicate that Levagen+ PEA is safe and effective in reducing the frequency of URTI episodes and relieving scratchy throats and coughing in individuals with URTI symptoms. I use PEA Luteolin Select from Moss Nutrition, which contains 300 mg of Levagen+ PEA and 50 mg of the flavonoid luteolin per capsule. PEA and luteolin have been shown to work synergistically in COVID-19-related illnesses such as Long COVID. I have patients take 1 capsule twice a day with meals of PEA Luteolin Select during COVID-19, cold, and flu season for prevention and then increase to 2 capsules three times a day when they feel like they're coming down with something. Hedberg Institute Members can download my latest upper respiratory tract infection protocols by logging in. Click here to learn more about the Hedberg Institute Membership.

There's still a lot we don't understand about the science of leaky gut. Does it cause disease or is it a symptom? What's the best way to test for it? Which treatments actually work to repair it?  Today's guest is one of the best people to begin to answer these questions.  Dr. Camilleri is a renowned gastroenterology researcher and professor at the Mayo Clinic.  Tune in to hear about cutting-edge innovations and informed understandings around leaky gut testing and treatment.  If you have any additional questions you would like answered in the future, let me know in the comments!   Watch/Read Next… What is Leaky Gut: https://drruscio.com/what-is-leaky-gut/  Leaky Gut Suplements: https://drruscio.com/leaky-gut-supplements/  Probiotics for Stomach Issues: https://drruscio.com/probiotics-for-stomach  Learn more about Dr. Camilleri's work: https://www.mayo.edu/research/faculty/camilleri-michael-m-d-d-sc/bio-00026245    Timestamps 00:00 Intro  03:25 Dr. Camilleri's background with leaky gut 05:05 Bile-acid supplementation  07:20 The small intestine  11:07 The prevalence of leaky gut  14:25 Leaky gut & diseases 20:08 Leaky gut & inflammation 30:18 Treatment: Where to start  36:09 Biomarkers of leaky gut 48:53 Leaky gut testing  53:24 Gluten intolerance prevalence  59:52 Food elimination & reintroduction  01:04:47 Prebiotics & FODMAPs 01:15:26 Probiotics   Featured Studies  What to do about the leaky gut: https://pubmed.ncbi.nlm.nih.gov/34509978/ Leaky gut: mechanisms, measurement and clinical implications in humans: https://pubmed.ncbi.nlm.nih.gov/31076401/ Development and Validation of Test for "Leaky Gut" Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults: https://pubmed.ncbi.nlm.nih.gov/33865841/  A case for improved assessment of gut permeability: a meta-analysis quantifying the lactulose:mannitol ratio in coeliac and Crohn's disease: https://pubmed.ncbi.nlm.nih.gov/35012471/  Food Emulsifiers and Metabolic Syndrome: The Role of the Gut Microbiota: https://pubmed.ncbi.nlm.nih.gov/35892789/ Food Additive Emulsifiers and Their Impact on Gut Microbiome, Permeability, and Inflammation: Mechanistic Insights in Inflammatory Bowel Disease: https://pubmed.ncbi.nlm.nih.gov/33336247/ Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity: https://pubmed.ncbi.nlm.nih.gov/32060130/ Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier: https://pubmed.ncbi.nlm.nih.gov/34371976/  Probiotics fortify intestinal barrier function: a systematic review and meta-analysis of randomized trials: https://pubmed.ncbi.nlm.nih.gov/37168869/  Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome: https://pubmed.ncbi.nlm.nih.gov/30108163/    Get the Latest Updates Facebook - https://www.facebook.com/DrRusciodc Instagram - https://www.instagram.com/drrusciodc/ Pinterest - https://www.pinterest.com/drmichaelrusciodc    DISCLAIMER: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Music featured in this video: "Modern Technology" by Andrew G, https://audiojungle.net/user/andrew_g  *Full transcript available on YouTube by clicking the “Show transcript” button on the bottom right of the video.

We've been using the same MS clinical course descriptors (relapsing-remitting, secondary progressive, and primary progressive) for almost three decades. As research has provided so much additional information and insight, is it time to update the way we describe, diagnose, and treat MS? The International Advisory Committee on Clinical Trials in Multiple Sclerosis has established a working group to explore this question. And, as a means of eliciting feedback from stakeholders around the world, a global survey was launched. The National MS Society's Chief Advocacy, Services, and Science Officer, Dr. Tim Coetzee, joins me to share the results of this survey, which may represent a first step toward delivering next-generation MS care. We're just two days away from the Hispanic/Latinx MS Experience Summit! We'll tell you why you don't want to miss this free online event, and we'll even tell you how to register. We're sharing the results of a study that provides strong evidence for adopting hematopoietic stem cell transplantation (aHSCT) as a standard treatment option for people living with relapsing-remitting MS. And we're sharing evidence from a Phase 3 clinical trial that demonstrates how cognitive behavioral therapy delivered over the internet significantly reduces depressive symptoms and improves the quality of life for people with MS. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: When it comes to adopting a new framework for describing MS, the survey says...  :22 The Hispanic-Latinx MS Experience Summit is just two days away! 2:02 Swedish study shows that autologous hematopoietic stem cell transplantation (aHSCT) is an effective treatment for adults with relapsing-remitting MS   3:41 Phase 3 clinical trial shows that cognitive behavioral therapy delivered over the internet significantly reduces depressive symptoms among people liviing with MS  6:07 Dr. Tim Coetzee shares the results of a global survey that asked whether it's time to update the way we describe, diagnose, and treat MS  9:36 Share this episode  27:21 Have you downloaded the free RealTalk MS app?  27:42 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/319 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Do the Current MS Clinical Course Descriptors Need to Change and If So, How?: A Survey of the MS Community https://journals.sagepub.com/doi/10.1177/13524585231196786 RealTalk MS Episode 280: How the Proposed Framework for Diagnosing and Treating MS Will Affect You with Dr. Tim Coetzee https://realtalkms.com/280 Register for the Hispanic/Latinx MS Experience Summit https://nationalmssociety.org/Resources-Support/Library-Education-Programs/Hispanic-Latinx-MS-Experience-Summit STUDY: Heaematopoietic Stem Cell Transplantation for Treating Multiple Sclerosis in Sweden: An Observational Cohort Study https://jnnp.bmj.com/content/early/2023/08/14/jnnp-2023-331864 National MS Society Recommendations for aHSCT-Bone Marrow Transplant for MS https://www.nationalmssociety.org/About-the-Society/News/National-MS-Society-Releases-Recommendations-for-a STUDY: Internet-Derived Cognitive Behavioural Therapy Programme to Reduce Depressive Symptoms in Patients with Multiple Sclerosis: A Multicentre, Randomised, Controlled Phase 3 Trial https://sciencedirect.com/science/article/pii/S2589750023001097 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 319 Guest: Dr. Tim Coetzee Privacy Policy

GO TO https://visit.therippleco.com/barrabruvvas TO GET 15% OFF YOUR ORDER!!!Another draft, another debut. Let us know the performance ratings in the comments. Welcome to Barra Bruvvas.Join the Bruvvahood:https://instagram.com/BarraBruvvashttps://twitter.com/BarraBruvvashttps://www.tiktok.com/@barrabruvvas Hosted on Acast. See acast.com/privacy for more information.

As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!_____________________________________________________________________________________Show notes, articles, and CME form can be found on our website: http://www.the-incubator.org/125/